A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in HCC previously treated with atezolizumab and bevacizumab (IMbrave251)
Locally Advanced or metastatic Hepatocellular Carcinoma (HCC) Who Have Progressed On Prior Systemic Treatment with Atezolizumab plus Bevacizumab Combination.
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Alice 03-79492120 (Research Room)
Beacon Hospital
PRINCIPAL INVESTIGATOR
Dr Tho Lye Mun
tholm@beaconhospital.com.my
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR WONG YOKE FUI
florencefui@yahoo.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Participant with Complete Radiological Response after Surgical Resection and Local Ablation
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR WONG YOKE FUI
florencefui@yahoo.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR LIM YUEH NI
ynlim1001@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
Adventist Penang
PRINCIPAL INVESTIGATOR
Dr. Ang Soo Fan
angsoofan@pah.com.my
04-222 7490/7491/7339
CONTACT
General line: 04-2227200
CRC: 04 222 7652 / 7653 (Tel)
researchcentre@pah.com.my (Email)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Alice 03-79492120 (Research Room)
An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)(BI1443-0002)
Recurrent/Metastatic Hepatocellular Carcinoma
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
DR LIM CHUN SEN
chunsen1@hotmail.com
CONTACT
General line: 07 – 356 5000
CRC: 07 – 356 5000 ext: 2408
Dr Munirah Admin Manager
drmunirah@hsi.gov.my (Email)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Kimee 03-79492120 (Research Room)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR SUHANA BINTI YUSAK
suhanayusak@gmail.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
Phase II/III Randomized, Controlled Clinical Study of AlloStim® VS. Physician’s Choice in Asian Subjects with Advanced Hepatocellular Carcinoma
Advance hepatocellular
Sultanah Bahiyah Hospital, Alor Setar
PRINCIPAL INVESTIGATOR
Zalwani Bt Zainuddin
CONTACT
Noor Kamila
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
LIM CHUN SEN
CONTACT
SC: Norhamiza Misri
CRC: 07 – 356 5000 ext: 2408
Dr Munirah Admin Manager
drmunirah@hsi.gov.my (Email)